Genmab — April 2015
-
Milestone på 10 mio. $ modtaget
-
"- Milestonebetalingen på 10 mio. dollar blev udløst som følge af fremskridt i det igangværende fase III-studie, hvor Daratumumab i kombination med Bortezomib, Melphalan og Prednisolon (VMP) sammenlignes med Bortezomib, Melphalan og Prednisolon alene som førstelinjebehandling af patienter, der ikke anses for at være kandidater til stamcelletransplantation (SCT), oplyser Genmab, der slutteligt fremhæver, at betalingen ikke påvirker selskabets resultatforventninger til 2015."
-
120281 de er endda købt højere end kurs 5. en del højere. men stadig i + i dag. Men den er jo kun lige startet. Regner med at have tjent et par mio. på den om et par år. Nu må vi se.
-
-
Human antibody targeting CD20 on cancerous B-cells
• Differentiated vs other CD20 mAb, targets slice of$8B market
Cancer
• Approved*
• US 1st Line CLL in combo w/ chlorambucil
• EU 1st Line CLL in combo w/ chlorambucil or
bendamustine
• Fludarabine and alemtuzumab refractory CLL
• Phase III trials in CLL & FL
• Partnered with Novartis
Autoimmune diseases (unapproved)
• Phase III trial ongoing in PV
• Relapsing remitting MS Ph III’s & pivotal NMO trials
announced
• Partnered with GSK
O -
Det satser vi på.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind